Our product portfolio includes both new products, which follow a New Drug Application (NDA) FDA regulatory pathway, and controlled-release generic products, which follow an Abbreviated New Drug Application (ANDA) pathway. Therapeutic areas covered by our portfolio include neurology, cardiovascular, GIT, pain and infection.